CA3081559A1 - Anti-cd40 antibody drug conjugates - Google Patents

Anti-cd40 antibody drug conjugates Download PDF

Info

Publication number
CA3081559A1
CA3081559A1 CA3081559A CA3081559A CA3081559A1 CA 3081559 A1 CA3081559 A1 CA 3081559A1 CA 3081559 A CA3081559 A CA 3081559A CA 3081559 A CA3081559 A CA 3081559A CA 3081559 A1 CA3081559 A1 CA 3081559A1
Authority
CA
Canada
Prior art keywords
drug conjugate
antibody drug
amino
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3081559A
Other languages
English (en)
French (fr)
Inventor
Adrian D. Hobson
Jason Z. OH
Michael J. Mcpherson
Wendy Waegell
Shaughn H. Bryant
Axel Hernandez, Jr.
Claire L. IHLE
Christopher C. MARVIN
Olivia A. PERNG
Ling C. Santora
Lu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CA3081559A1 publication Critical patent/CA3081559A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3081559A 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates Pending CA3081559A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US62/593,807 2017-12-01
US201762595045P 2017-12-05 2017-12-05
US62/595,045 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
CA3081559A1 true CA3081559A1 (en) 2019-06-06

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3081559A Pending CA3081559A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Country Status (19)

Country Link
US (1) US20220265842A1 (https=)
EP (1) EP3716982A4 (https=)
JP (1) JP2021504430A (https=)
KR (1) KR20200095493A (https=)
CN (1) CN111465399A (https=)
AU (1) AU2018374633A1 (https=)
BR (1) BR112020010691A2 (https=)
CA (1) CA3081559A1 (https=)
CL (1) CL2020001442A1 (https=)
CR (1) CR20200285A (https=)
DO (1) DOP2020000119A (https=)
EC (1) ECSP20034868A (https=)
IL (1) IL274650A (https=)
MX (1) MX2020005465A (https=)
PE (1) PE20201464A1 (https=)
PH (1) PH12020550551A1 (https=)
RU (1) RU2020117156A (https=)
SG (1) SG11202004865SA (https=)
WO (1) WO2019106608A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271964A (zh) 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
AU2022205664A1 (en) * 2021-01-07 2023-08-17 Immunext, Inc. NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF
CA3207416A1 (en) * 2021-02-04 2022-08-11 Lingjian ZHU Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
CN117580849A (zh) * 2021-06-24 2024-02-20 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
CN120463762A (zh) * 2021-08-26 2025-08-12 映恩生物科技(上海)有限公司 一种甾体化合物及其缀合物
US20250179114A1 (en) * 2021-09-14 2025-06-05 Duality Biologics (Suzhou) Co., Ltd. Anti-Inflammatory Compound and Use Thereof
KR102835682B1 (ko) * 2022-06-16 2025-07-22 애브비 바이오테라퓨틱스 인크. 항-cd19 항체-약물 접합체
CN120239705A (zh) 2022-07-21 2025-07-01 萤火虫生物股份有限公司 糖皮质激素受体激动剂和其缀合物
JP2025532110A (ja) * 2022-09-22 2025-09-29 イーライ リリー アンド カンパニー グルココルチコイド受容体アゴニスト
TW202432588A (zh) * 2022-12-28 2024-08-16 大陸商蘇州盛迪亞生物醫藥有限公司 一種cd40結合分子的組成物及醫藥用途
TW202430226A (zh) * 2022-12-28 2024-08-01 大陸商上海盛迪醫藥有限公司 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4686650B2 (ja) * 2007-11-30 2011-05-25 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
WO2009085879A2 (en) * 2007-12-21 2009-07-09 Schering Corporation C20-c21 substituted glucocorticoid receptor agonists
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
CN107810198B (zh) * 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
US20180126000A1 (en) * 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Also Published As

Publication number Publication date
SG11202004865SA (en) 2020-06-29
JP2021504430A (ja) 2021-02-15
ECSP20034868A (es) 2020-08-31
WO2019106608A1 (en) 2019-06-06
DOP2020000119A (es) 2020-08-31
IL274650A (en) 2020-06-30
US20220265842A1 (en) 2022-08-25
MX2020005465A (es) 2020-09-07
PE20201464A1 (es) 2020-12-17
KR20200095493A (ko) 2020-08-10
PH12020550551A1 (en) 2021-03-22
AU2018374633A1 (en) 2020-05-21
CR20200285A (es) 2020-09-04
RU2020117156A (ru) 2022-01-04
EP3716982A4 (en) 2021-08-11
CL2020001442A1 (es) 2020-09-11
BR112020010691A2 (pt) 2020-11-10
CN111465399A (zh) 2020-07-28
EP3716982A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
CA3081559A1 (en) Anti-cd40 antibody drug conjugates
EP3658192B1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
AU2018342527B2 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
EP3538539B1 (en) Steroids and protein-conjugates thereof
KR102877468B1 (ko) 흔적이 없는 링커 및 이의 단백질-접합체
CA3098453A1 (en) Anti-msr1 antibodies and methods of use thereof
KR20200108002A (ko) 스테로이드 및 이의 항체-접합체
KR20200085807A (ko) 항체 약물 접합제용 친수성 링커
WO2018140831A2 (en) Tumor targeting conjugates and methods of use thereof
CA3049842A1 (en) Construct-peptide compositions and methods of use thereof
JP2024502360A (ja) 新規ステロイドペイロード、ステロイドリンカー、含有するａｄｃ、及びその使用
US20240415919A1 (en) Compositions and methods for treatment of autoimmune disorders and cancer
HK40032698A (en) Anti-cd40 antibody drug conjugates
EP3322733B1 (en) Hide1 compositions and methods
HK40031135A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
HK40031135B (en) Glucocorticoid receptor agonist and immunoconjugates thereof